Osanni Bio Raises $190M in Series B Funding Led by Patient Square Capital

The round also saw participation from the Horowitz Group, Invus Opportunities, and the Retinal Degeneration Fund.

The company plans to use the funding to advance its existing pipeline of programs and expand its discovery and development capabilities.

Osanni is led by a team of experienced inventors and entrepreneurs with a strong history of building and commercializing successful companies.

Read More:Tetrix Raises $15M in Series A Funding Led by White Star Capital

"At Osanni, we are accelerating the process of medicine discovery by leveraging biodesign-inspired innovation, modern technology and a focus on capital efficiency,” said Michael Ackermann, Ph.D., Founder and Chief Executive Officer of Osanni Bio. “Patient Square is the perfect partner for scaling our vision, and I couldn't be more excited to build our future with them.”

Neel Varshney, M.D., Founding Partner of Patient Square, said, “We are excited to partner with Osanni to build a new model for discovering and developing innovative medicines for patients with significant unmet need. Osanni’s approach pairs deep scientific insight with capital efficiency, creating a platform for differentiated, repeatable success to advance novel therapies and deliver meaningful impact for patients.”

About Osanni Bio

Founded by Michael Ackermann and headquartered in San Francisco, California, Osanni Bio is a therapeutics development company focused on discovering and advancing new medicines. Its core innovation platform is designed to generate scientific insights, create novel drug candidates, and efficiently move programs toward proof-of-concept. Once a program has been sufficiently validated, it is spun out into a dedicated affiliate company with the specialized talent, resources, and focus needed to continue development and growth.

Read More:Concord Raises $3M in Seed Funding to Build Agentic Execution